Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMA-203 + mRNA-4203 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMA-203 | IMA203|IMA 203|ACTengine IMA203 | IMA-203 is a preparation of autologous T-cells engineered to express T-cell receptors (TCR) that target tumor-associated antigens, which potentially results in enhanced immune response against tumor cells (NCI Drug Dictionary). | ||
| mRNA-4203 | mRNA4203|mRNA 4203 | Limited information is currently available on mRNA-4203 (Aug 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06946225 | Phase I | IMA-203 + mRNA-4203 | ACTengine IMA203 Combined With mRNA-4203 | Recruiting | USA | 0 |